Orqueda Andrés Javier, Giménez Carla Alejandra, Pereyra-Bonnet Federico
Basic Science and Experimental Medicine Institute, University Institute of the Italian Hospital, Juan D. Perón 4190, C1181ACH Buenos Aires, Argentina.
Stem Cells Int. 2016;2016:5934782. doi: 10.1155/2016/5934782. Epub 2016 Jan 6.
When Dolly the sheep was born, the first probe into an adult mammalian genome traveling back in time and generating a whole new animal appeared. Ten years later, the reprogramming process became a defined method of producing induced pluripotent stem cells (iPSCs) through the overexpression of four transcription factors. iPSCs are capable of originating virtually all types of cells and tissues, including a whole new animal. The reprogramming strategies based on patient-derived cells should make the development of clinical applications of cell based therapy much more straightforward. Here, we analyze the current state, opportunities, and challenges of iPSCs from bench to bed, including organoids and the CRISPR system.
当绵羊多莉诞生时,首次出现了对成年哺乳动物基因组进行逆向溯源并培育出全新动物的探索。十年后,重编程过程成为一种通过过表达四种转录因子来产生诱导多能干细胞(iPSC)的明确方法。iPSC能够分化产生几乎所有类型的细胞和组织,包括培育出全新的动物。基于患者来源细胞的重编程策略应会使基于细胞的治疗的临床应用开发变得更加直接。在此,我们分析了iPSC从实验室到临床应用的当前状况、机遇和挑战,包括类器官和CRISPR系统。